SHANK3 and cancer: SH3 and multiple ankyrin repeat domains 3 (SHANK3) has been implicated in inhibiting integrin function in cancer cells by binding to and sequestering active Rap1–GTP through its N-terminal SPN domain, thus limiting Rap1–GTP bioavailability at the plasma membrane (Lilja et al., 2017).